13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuropharmacology and Novel Drug Development
The field of neuropharmacology and novel drug development delves into the biochemical pathways and molecular targets underlying neurological function and dysfunction. This research area is pivotal in driving the creation of innovative drugs, ranging from neuroprotective agents to neuromodulators. Advanced methodologies, such as CRISPR-based genome editing and nanotechnology, are transforming the delivery and effectiveness of neurotherapeutics. Researchers are also focusing on strategies to overcome the challenges of the blood-brain barrier, ensuring enhanced drug delivery to the central nervous system. With a strong focus on addressing unmet clinical needs, neuropharmacology is expanding the frontiers of science, paving the way for groundbreaking solutions to neurological and psychiatric disorders.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Examining the effects of prenatal neurotoxin exposure on the development of the prefrontal cortex and its impact on executive functioning and attentional capacities in children
David Joseph Sperbeck, Private practice, United States
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Mapping the cytokine landscape in Alzheimer’s disease: A bibliometric analysis of global trends and emerging themes
Ananya Rajasekaran, ThinkNeuro, United States